WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Pancreatic cancer is one of the most fatal cancer types characterized by an increased incidence in western industrialized countries. Metabolic syndrome (MetS) has become a major public health problem. However, evidence on the effects of MetS and its components on the risk of pancreatic cancer is limited, and the potential mechanisms underlying the association remain unclear. Based on the prospective UK Biobank cohort, this study identified the dominant MetS components related to pancreatic cancer, examined the potential non-linear associations between MetS components and pancreatic cancer and evaluated the joint effect of MetS and C-reactive protein, a sensitive biochemical indicator to assess varying inflammatory status, with pancreatic cancer risk. Results showed that MetS is associated with increased risk of pancreatic cancer in general population. Waist circumference and fasting blood glucose were two predominant MetS components that might be independently associated with pancreatic cancer risk in a linear manner. Our results suggested a potential joint effect of MetS and CRP in pancreas tumorigenesis, and provide novel insights underlying the pathological changes for pancreatic cancer development.
Metabolism syndrome and risk of cancer
The metabolic syndrome (MetS) is a cluster of the most dangerous heart attack risk factors: diabetes and prediabetes, abdominal obesity, high cholesterol and high blood pressure. It affects around 20-25 percent of adults in the world. Previous studies have observed associations between MetS and cancer development and cancer-related deaths. However, it's still unclear which MetS components are more harmful, and whether the harmful effect are additive. For MetS and risk of certain site-specific cancer, the current evidence is still unclear. We therefore proposed this study to comprehensively evaluate MetS and cancer. We have three aims:
1. To investigate the MetS and subsequent overall and site-specific cancer risk/death
2. To investigate individual components of MetS and cancer risk/death
3. To investigate the interaction of individual components of MetS, in relation with cancer risk/ death
This is a 2-year project. We will carry out a comprehensive analysis of MetS and cancer risk. The results will provide robust evidence for the management of MetS as well as the development of cancer prevention strategies.